Mometasonfuroat Cipla (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasonfuroat Cipla, is a glucocorticoid presented as a nasal spray for nasal use. It treats allergic rhinitis, including seasonal forms, by reducing inflammation of the nasal passages in adults and children, and improves nasal airflow.

GNH USA supplies Mometasonfuroat Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for bulk and individual orders across diverse healthcare markets, with dedicated technical support and compliance documentation.

Mometasone furoate nasal spray acts on inflammatory pathways of the nasal mucosa to relieve allergic symptoms.

Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea, leading to improved breathing and comfort. Seasonal allergic rhinitis: alleviates symptoms triggered by pollen, mold spores or other seasonal allergens, helping maintain daily activities during peak seasons. Perennial allergic rhinitis: provides sustained control of year‑round nasal inflammation, decreasing chronic symptoms and the need for additional rescue medications.

Mometasone furoate nasal spray may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of nasal passages - Sneezing - Epistaxis (nosebleed)

Serious or Rare Side Effects: - Nasal septal perforation - Cataracts or glaucoma with prolonged use - Suppression of the hypothalamic‑pituitary‑adrenal axis

Before using Mometasonfuroat Cipla, consider the following precautions to ensure safe and effective therapy.

Pregnancy: consult a healthcare professional before use, as safety data are limited. Elderly patients: monitor for increased sensitivity to glucocorticoid effects. Concurrent nasal infections: avoid use until infection resolved to prevent worsening. Long‑term use: periodic assessment of nasal mucosa and intra‑ocular pressure is recommended. Systemic absorption: limit use to prescribed dose to reduce risk of adrenal suppression. Store at room temperature: keep below 25 °C, protect from moisture and direct sunlight in the original packaging.

Mometasone furoate nasal spray can interact with certain medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce steroid exposure and diminish therapeutic effect. - Systemic corticosteroids: concurrent use can increase risk of systemic glucocorticoid side effects.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase local steroid levels, watch for local irritation. - Antihistamines: may have additive effect on nasal symptom relief, monitor for excessive dryness. - Immunosuppressants: monitor for heightened infection risk when combined with high‑dose steroids.